During the recent session, Palisade Bio Inc (NASDAQ:PALI)’s traded shares were 2.22 million, with the beta value of the company hitting 1.35. At the last check today, the stock’s price was $2.41, reflecting an intraday loss of -22.24% or -$0.69. The 52-week high for the PALI share is $22.35, that puts it down -827.39 from that peak though still a striking -24.9% loss since the share price plummeted to a 52-week low of $3.01. The company’s market capitalization is $2.85M, and the average intraday trading volume over the past 10 days was 94360.0 shares, and the average trade volume was 31.82K shares over the past three months.
Palisade Bio Inc (PALI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. PALI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -3.35.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Palisade Bio Inc (NASDAQ:PALI) trade information
Palisade Bio Inc (PALI) registered a -22.24% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -22.24% in intraday trading to $2.41, hitting a weekly high. The stock’s 5-day price performance is -30.33%, and it has moved by -29.10% in 30 days. Based on these gigs, the overall price performance for the year is -71.04%. The short interest in Palisade Bio Inc (NASDAQ:PALI) is 16674.0 shares and it means that shorts have 0.74 day(s) to cover.
The consensus price target of analysts on Wall Street is $1.5, which implies a decrease of -60.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.5 and $1.5 respectively. As a result, PALI is trading at a premium of 37.76% off the target high and 37.76% off the low.
Palisade Bio Inc (PALI) estimates and forecasts
Statistics show that Palisade Bio Inc has outperformed its competitors in share price, compared to the industry in which it operates. Palisade Bio Inc (PALI) shares have gone down -66.93% during the last six months, with a year-to-date growth rate more than the industry average at 51.43% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 49.20% this quarter and then jump 63.90% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 75.28%. While earnings are projected to return 50.63% in 2024.
PALI Dividends
Palisade Bio Inc is due to release its next quarterly earnings on 2024-Nov-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Palisade Bio Inc (NASDAQ:PALI)’s Major holders
Palisade Bio Inc insiders own 1.81% of total outstanding shares while institutional holders control 2.89%, with the float percentage being 2.94%.
